留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

肾移植患者用他克莫司替换环孢素A后的疗效及不良反应的回顾性分析

卫泽武,  张文文,  马多玲,  毕娟,  谌介秀,  杨云云

downloadPDF
文章导航 > 药学实践与服务  > 2018 >  36(1): 75-79
卫泽武, 张文文, 马多玲, 毕娟, 谌介秀, 杨云云. 肾移植患者用他克莫司替换环孢素A后的疗效及不良反应的回顾性分析[J]. 药学实践与服务, 2018, 36(1): 75-79. doi: 10.3969/j.issn.1006-0111.2018.01.016
引用本文: 卫泽武, 张文文, 马多玲, 毕娟, 谌介秀, 杨云云. 肾移植患者用他克莫司替换环孢素A后的疗效及不良反应的回顾性分析[J]. 药学实践与服务, 2018, 36(1): 75-79. doi: 10.3969/j.issn.1006-0111.2018.01.016
shu
WEI Zewu, ZHANG Wenwen, MA Duoling, BI Juan, CHEN Jiexiu, YANG Yunyun. A retrospective analysis of the efficacy and adverse reactions for the renal transplant patients conversed from cyclosporine A to tacrolimus[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(1): 75-79. doi: 10.3969/j.issn.1006-0111.2018.01.016
Citation: WEI Zewu, ZHANG Wenwen, MA Duoling, BI Juan, CHEN Jiexiu, YANG Yunyun. A retrospective analysis of the efficacy and adverse reactions for the renal transplant patients conversed from cyclosporine A to tacrolimus[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(1): 75-79. doi: 10.3969/j.issn.1006-0111.2018.01.016
shu

肾移植患者用他克莫司替换环孢素A后的疗效及不良反应的回顾性分析

doi: 10.3969/j.issn.1006-0111.2018.01.016

  • 第二军医大学附属长海医院药学部, 上海 200433

A retrospective analysis of the efficacy and adverse reactions for the renal transplant patients conversed from cyclosporine A to tacrolimus

  • Department of Pharmacy, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China

  • 摘要: 目的 研究肾移植患者用基础免疫抑制剂他克莫司替换环孢素A后的疗效与不良反应。 方法 收集他克莫司替换环孢素A的肾移植患者随访资料，使用SPSS17.0分析替换后1年内相关药源性疾病（DIDs）和急性排异反应（AR）的改善情况。 结果 肾移植患者用他克莫司替换环孢素A后的1年内，慢性爬行肌酐升高（CScr）者和AR者的血肌酐（Scr）及尿素氮（BUN）均逐渐下降，两者有显著性差异（P<0.05或P<0.01）；药物性肝损伤（DILI）者的总胆红素（TB）和直接胆红素（DB）逐渐下降，并呈显著性差异（P<0.05或P<0.01），第12个月转氨酶（ALT）显著降低（P<0.05）；牙龈增生（GO）现象停止。然而，空腹血糖（FBG）在第12个月显著升高（P<0.05）。 结论 使用环孢素A的肾移植患者，若发生环孢素相关的AR和（或）其所致DIDs，可用他克莫司替换，但需警惕换药所致的肾移植后新发糖尿病。
    Abstract: Objective To study the efficacy and adverse reactions for renal transplant patients conversed from cyclosporine A to tacrolimus. Methods The follow-up data of renal transplant patients conversed from cyclosporine A to tacrolimus were collected. The clinical therapeutic outcomes including drug induced diseases (DIDs) and acute rejection (AR) induced by cyclosporine A were analyzed during the first year after conversion with SPSS17.0 software. Results The levels of Scr and BUN were significantly decreased during the first year after conversion for renal transplant patients with CScr and AR (P<0.05 or P<0.01). The levels of direct bilirubin (DB) and total bilirubin (TB) were also significantly lowed (P<0.05 or P<0.01) during the first year for drug-induced liver injury (DILI) patients. The average level of ALT was significantly decreased in 12 months after conversion (P<0.05). The complications of gingival overgrowth (GO) stopped with the medication replacement. However, the fasting blood glucose (FBG) level increased significantly in 12 months after conversion (P<0.05). Conclusion For renal transplant patients suffered from AR or the serious DIDs induced by cyclosporine A, conversion from cyclosporine A to tacrolimus could be considered. However, it should be aware of the high blood glucose or the new diabetes caused by tacrolimus.
  • [1] Halloran PF. Immunosuppressive drugs for kidney transplantation[J]. N Engl J Med, 2004,351(26):2715-2729.
    [2] Krämer BK, Montagnino G, Krüger B, et al. Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation:7-year observational results[J]. Transpl Int, 2016,29(3):307-314.
    [3] Ateyya H. Amelioration of cyclosporine induced nephrotoxicity by dipeptidyl peptidase inhibitor vildagliptin[J]. Int Immunopharmacol, 2015,28(1):571-577.
    [4] Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy[J]. N Engl J Med, 2003, 349(24):2326-2333.
    [5] Gau CH, Tu HP, Chin YT, et al. Can chlorhexidine mouthwash twice daily ameliorate cyclosporine-induced gingival overgrowth?[J]. J Formos Med Assoc, 2013,112(3):131-137.
    [6] Wadei HM, Textor SC. Hypertension in the kidney transplant recipient[J]. Transplant Rev (Orlando), 2010,24(3):105-120.
    [7] Rezzani R. Cyclosporine A and adverse effects on organs:histochemical studies[J]. Prog Histochem Cytochem,2004,39(2):85-128.
    [8] Kamel M, Kadian M, Srinivas T, et al. Tacrolimus confers lower acute rejection rates and better renal allograft survival compared to cyclosporine[J].World J Transplant,2016, 6(4):697-702.
    [9] Franke GH, Trampenau C, Reimer J, et al. Switching from cyclosporine to tacrolimus leads to improved disease-specific quality of life in patients after kidney transplantation[J]. Transplant Proc, 2006,38(5):1293-1294.
    [10] Videla CO. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy[J]. Transplant Proc, 2009,41(6):2659-2663.
    [11] Margreiter R, Pohanka E, Sparacino V, et al. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects[J]. Transpl Int, 2005,18(7):816-823.
    [12] 黄晓宁,陈小娟,李勇. 肾移植术后患者应用他克莫司与环孢素A发生急性排斥反应的Meta分析[J].中国医院用药评价与分析,2016,16(5):636-639.
    [13] Tao Y, Hu L, Li S, et al. Tranilast prevents the progression of chronic cyclosporine nephrotoxicity through regulation of transforming growth factor β/Smad pathways[J].Transplant Proc,2011,43(5):1985-1988.
    [14] Seeland S, Török M, Kettiger H, et al. A cell-based, multiparametric sensor approach characterises drug-induced cytotoxicity in human liver HepG2 cells[J]. Toxicol In Vitro, 2013,27(3):1109-1120.
    [15] Cond SAP, Bastos MG, Vieira BJ, et al. Down-regulation of transforming growth factor beta-2 expression is associated with the reduction of cyclosporin induced gingival overgrowth in rats treated with roxithromycin:an experimental study[J]. BMC Oral Health,2009,9(1):33.
    [16] Al-Hamilly NS, Radwan LR, Abdul-Rahman M, et al. Biological roles of KGF, CTGF and TGF-β in cyclosporine-A-and phenytoin-induced gingival overgrowth:A comparative experimental animal study.[J]. Arch Oral Biol,2016,66:38-43.
    [17] 余爱华,辛华雯,吴笑春,等.环孢素和他克莫司对肾移植后发生糖尿病的影响研究[J]. 中国药师, 2011,14(4):521-523.
    [18] Sinangil A, Celik V, Barlas S, et al. New-onset diabetes after kidney transplantation and pretransplant hypomagnesemia[J]. Prog Transplant, 2016, 26(1):55-61.
  • [1] 王鹏, 陈顺, 赵逸, 高守红, 王志鹏.  卡培他滨致小鼠手足综合征模型的建立及评价 . 药学实践与服务, 2024, 42(9): 385-388, 398. doi: 10.12206/j.issn.2097-2024.202308045
    [2] 陈春娟, 郑志新, 李骊.  平喘方联合孟鲁司特钠治疗儿童支气管哮喘患者的临床疗效观察 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202405035
    [3] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [4] 宋红卫, 王燕, 方铭, 马云鹏, 钟超, 徐一新, 徐峰, 周婷.  2021−2023年我院药品不良反应的特点分析 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202404041
    [5] 丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉.  消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
    [6] 张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一.  药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
    [7] 丁千雪, 尚圣兰, 余梦辰, 余爱荣.  机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3487
  • HTML全文浏览量:  470
  • PDF下载量:  843
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-02-20
  • 修回日期:  2017-06-30

肾移植患者用他克莫司替换环孢素A后的疗效及不良反应的回顾性分析

doi: 10.3969/j.issn.1006-0111.2018.01.016
  • 第二军医大学附属长海医院药学部, 上海 200433
  • 收稿日期: 2017-02-20
  • 修回日期: 2017-06-30

摘要: 目的 研究肾移植患者用基础免疫抑制剂他克莫司替换环孢素A后的疗效与不良反应。 方法 收集他克莫司替换环孢素A的肾移植患者随访资料，使用SPSS17.0分析替换后1年内相关药源性疾病（DIDs）和急性排异反应（AR）的改善情况。 结果 肾移植患者用他克莫司替换环孢素A后的1年内，慢性爬行肌酐升高（CScr）者和AR者的血肌酐（Scr）及尿素氮（BUN）均逐渐下降，两者有显著性差异（P<0.05或P<0.01）；药物性肝损伤（DILI）者的总胆红素（TB）和直接胆红素（DB）逐渐下降，并呈显著性差异（P<0.05或P<0.01），第12个月转氨酶（ALT）显著降低（P<0.05）；牙龈增生（GO）现象停止。然而，空腹血糖（FBG）在第12个月显著升高（P<0.05）。 结论 使用环孢素A的肾移植患者，若发生环孢素相关的AR和（或）其所致DIDs，可用他克莫司替换，但需警惕换药所致的肾移植后新发糖尿病。

English Abstract

卫泽武, 张文文, 马多玲, 毕娟, 谌介秀, 杨云云. 肾移植患者用他克莫司替换环孢素A后的疗效及不良反应的回顾性分析[J]. 药学实践与服务, 2018, 36(1): 75-79. doi: 10.3969/j.issn.1006-0111.2018.01.016
引用本文: 卫泽武, 张文文, 马多玲, 毕娟, 谌介秀, 杨云云. 肾移植患者用他克莫司替换环孢素A后的疗效及不良反应的回顾性分析[J]. 药学实践与服务, 2018, 36(1): 75-79. doi: 10.3969/j.issn.1006-0111.2018.01.016
shu
WEI Zewu, ZHANG Wenwen, MA Duoling, BI Juan, CHEN Jiexiu, YANG Yunyun. A retrospective analysis of the efficacy and adverse reactions for the renal transplant patients conversed from cyclosporine A to tacrolimus[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(1): 75-79. doi: 10.3969/j.issn.1006-0111.2018.01.016
Citation: WEI Zewu, ZHANG Wenwen, MA Duoling, BI Juan, CHEN Jiexiu, YANG Yunyun. A retrospective analysis of the efficacy and adverse reactions for the renal transplant patients conversed from cyclosporine A to tacrolimus[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(1): 75-79. doi: 10.3969/j.issn.1006-0111.2018.01.016
shu

    全文HTML

参考文献 (18)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计